EMA Updates Board On Business Continuity And Coronavirus
Plan Safeguards Core Agency Activities In Light Of Coronavirus Pandemic
Executive Summary
The European Medicines Agency’s first management board meeting of 2020 was held virtually and was shortened but covered a number of topics including COVID-19.
You may also be interested in...
EMA Postpones Events, Holds Virtual Meetings To Cut COVID-19 Risk
The European medicines regulator wants to restrict the number of visitors coming to its offices to reduce the risk of coronavirus infection.
The Stakes Are High So Get It Right: CHMP Oral Explanations & FDA AdComs
The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. How they perform is critical. Consultant Kate Dion has a raft of helpful tips for companies facing this daunting situation. Neena Brizmohun reports.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.